Observational studyDiabetes, obesity & metabolism2019

Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.

Anna Norhammar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.